Global Hyperphosphatemia Drugs Market CAGR Growth of 10.71% overy Four Years - Analysis, Technologies & Forecast 2015-2019

Dec 17, 2015, 08:10 ET from Research and Markets

DUBLIN, Dec. 17, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/x428rl/global) has announced the addition of the "Global Hyperphosphatemia Drugs Market 2015-2019" report to their offering.

The report forecasts the global hyperphosphatemia drugs market to grow at a CAGR of 10.71% over the period 2014-2019.

In this report, the author the present scenario and growth prospects of the global hyperphosphatemia drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of branded, generic, OTC, and off-label drugs used for treating hyperphosphatemia.

Market drivers:

  • Increased number of people undergoing dialysis

Market challenges:

  • Non-adherence to treatment regimens

Market trends:

  • Patient assistance programs

Questions Answered:

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key Market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Companies Mentioned Include:

  • Fresenius Medical Care
  • Keryx Biopharmaceuticals
  • Sanofi
  • Shire
  • Vifor Pharma
  • Alkem
  • Amgen
  • Ardelyx
  • AstraZeneca
  • Baxter
  • Bayer
  • Chugai Pharmaceutical
  • Japan Tobacco
  • Kissei Pharmaceutical
  • Sandoz
  • Synthon
  • Torri Pharmaceutical

Report Structure:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Market research methodology

PART 04: Product profiles

PART 05: Introduction

PART 06: Disease Overview

PART 07: Key developments in hyperphosphatemia therapy

PART 08: Guidelines for use of phosphate binders

PART 09: Pipeline analysis

PART 10: Market landscape

PART 11: Hyperphosphatemia management market dynamics

PART 12: Market segmentation by dosage form

PART 13: Market segmentation by formulation

PART 14: Geographical segmentation

PART 15: Key leading countries

PART 16: Market drivers

PART 17: Impact of drivers

PART 18: Market challenges

PART 19: Impact of drivers and challenges

PART 20: Market trends

PART 21: Vendor landscape

PART 22: Key vendor analysis

PART 23: Appendix

For more information visit http://www.researchandmarkets.com/research/x428rl/global

Media Contact:

Laura Wood, +353-1-481-1716, press@researchandmarkets.net

 

SOURCE Research and Markets



RELATED LINKS

http://www.researchandmarkets.com